Engineering Anisotropic Biomimetic Fibrocartilage Microenvironment by Bioprinting Mesenchymal Stem Cells in Nanoliter Gel Droplets

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation

Published Version
doi:10.1021/mp400573g

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:14065554

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
ABSTRACT: Over the past decade, bioprinting has emerged as a promising patterning strategy to organize cells and extracellular components both in two and three dimensions (2D and 3D) to engineer functional tissue mimicking constructs. So far, tissue printing has neither been used for 3D patterning of mesenchymal stem cells (MSCs) in multiphase growth factor embedded 3D hydrogels nor been investigated phenotypically in terms of simultaneous differentiation into different cell types within the same multidimensional 3D tissue constructs. Accordingly, we demonstrated a biochemical gradient by bioprinting nanoliter droplets encapsulating human MSCs, bone morphogenetic protein 2 (BMP-2), and transforming growth factor β1 (TGF-β1), engineering an anisotropic biomimetic fibrocartilage microenvironment. Assessment of the model tissue construct displayed multiphasic anisotropy of the incorporated biochemical factors after patterning. Quantitative real time polymerase chain reaction (qRT-PCR) results suggested genomic expression patterns leading to simultaneous differentiation of MSC populations into osteogenic and chondrogenic phenotype within the multiphasic construct, evidenced by upregulation of osteogenesis and condrogenesis related genes during in vitro culture. Comprehensive phenotypic network and pathway analysis results, which were based on genomic expression data, indicated activation of differentiation related mechanisms, via signaling pathways, including TGF, BMP, and vascular endothelial growth factor.

KEYWORDS: 3D bioprinting, micropatterning, biomimetic tissue platforms, functional tissue models, tissue interfaces, genomic expression analysis

INTRODUCTION

Recent advances in tissue engineering have enabled engineered 3D tissue structures for various applications, including regenerative medicine and in vitro biomimetic functional tissue platforms.1–16 Engineered 3D tissue models that mimic native tissues have emerged and started playing an important role in drug discovery and development.17–19 The need for complex microengineered 3D methods for tissue engineering applications is well accepted due to the limitations of 2D systems in effectively representing the complex tissue environment.20–22 Current 3D tissue scaffolding methods present shortcomings due to lack of control over spatial and temporal control over cell seeding and...
extracellular matrix (ECM) composition. To engineer 3D biomimetic multiphase complex tissue structures such as tissue interfaces, it is critical to have control over the microenvironment components, including cellular, extracellular, and biological factor gradients in microscale. As a result of recent advances in stem cell biology, it is possible to control microenvironments which can direct controlled differentiation of cells and, hence, facilitate reorganization of the bioengineered structures toward a specific tissue phenotype.

Designs involving single-phasic, dual-phasic, and continuous-gradation scaffolds have been developed. However, the small scale of the tissue interfaces (Figure 1A,B), which range from 50 μm to 2 mm in length (depending on tissue, species, and age), presents significant challenges in engineering the microscale anisotropy observed in extracellular, biochemical, and cellular composition. Therefore, in the case of interface tissue engineering, there is an unmet need for advanced biomanufacturing methods to mimic the intricate microscale 3D anisotropic environment with precision. Bioprinting can overcome the limitations of existing tissue scaffolding methods in interface tissue engineering by providing control over encapsulation and patterning of the cells and the accompanying ECM components in microscale.

Bioprinting involves the use of computer-aided transfer processes for patterning and assembling living and nonliving materials with a prescribed 2D or 3D organization to produce bioengineered structures serving in regenerative medicine, drug discovery, and basic cell biology studies. Bioprinting, biomaterializing, and multilayer fabrication methods have been used to control cell patterning and seeding in this study, we expand the use of microscale bioprinting to facilitate engineering of the complex anisotropic fibrocartilage tissue phase via nanoliter encapsulation and printing of MSCs along with biochemical factors and ECM components (Figure 1C,D). MSCs were used in this study as they are the common progenitors of musculoskeletal tissues, including bone and cartilage.

Phenotypic characterization of cells within in vitro culture models by genomic expression analysis provides essential genetic indicators and high-content biomarkers for drug testing and for studying the impact of uncharacterized perturbations on cells. In this work, we investigated the state of the patterned cells within the 3D multiphasic tissue constructs in terms of a comprehensive genomic expression analysis, which is directly relevant to development of new in vitro functional models and their use in drug discovery. Through genomic expression analysis, we demonstrate the potential of bioprinting in engineering functional biomimetic multiphase 3D tissue models, such as the fibrocartilage phase at the soft and hard tissue interface.

### EXPERIMENTAL SECTION

#### Micropatterning and in Vitro Culture of Fibrocartilage Phase

A computer-aided design of the bioprinting pathway was first generated (Figure 2A) for each experimental group. Microdroplets of Bioinks were generated in a sterile laminar flow hood under controlled humidity by cell-encapsulating droplet generation system developed in our laboratory. Using the valve-based droplet ejector setup, the Bioink droplets composed of cell encapsulating hydrogel were printed on gel-coated substrates (Transwell permeable culture inserts, Corning Inc., Figure 2B). The nominal droplet size was around 300 μm in diameter following deposition on the substrate (Figure 2C,D). The interdroplet distance was determined by the size of the droplets residing on the substrate, which was around 700 μm measured from center to center (Figure 2D). Multiple layers of these droplets were printed and photo-cross-linked layer-by-layer using ultraviolet light (UV) at a power setting of 6.9 mW/cm² for 30 s based on earlier work. Bioprinted and photo-cross-linked multiple layers were merged forming a seamless and continuous 3D tissue structure (Figure 2D). Methacrylated gelatin precursor solution (5%) with photoinitiator for photocross-linking (0.5%, Irgacure 2959) was used as the major constituent of the Bioink, as we described previously. Diffusion and integration of the phases were assessed using the fluorescent Rhodamine B (red; 0.04 mM) and Dextran-Alexa Fluor 488 (green; 0.01 mM; 10 kDa). To bioprint the fibrocartilage phase, hydrogel solution was supplemented with human MSCs (hMSCs, Lonza) at a concentration of 10⁶ cells per milliliter of hydrogel and growth factors (BMP-2 at 20 ng per mL of hydrogel; TGF-β1 at 10 ng per mL of hydrogel; human recombinant growth factors from R&D Systems). To maintain cellular viability during bioprinting, Bioink was supplemented with 0.01 mM; 10 kDa). Tissue bioengineered structures serving in regenerative medicine, drug discovery, and basic cell biology studies.
with 10% culture medium and the pH was neutralized to 7.0 using 0.1 M sodium hydroxide solution. hMSCs were mixed into the Bioink and patterned in microdroplets with BMP-2 and TGF-β1 growth factors in single phase or multiphase pattern representing the fibrocartilage phase. We evaluated four different Bioink compositions to investigate the effect of bioprinting based patterning on engineered fibrocartilage phase: (1) multiphase TGF-β1 and BMP-2 patterning with hMSCs, (2) single phase TGF-β1 patterning with hMSCs, (3) single phase BMP-2 patterning with hMSCs, and (4) control (no growth factors, hMSCs only). The culture medium was composed of α-MEM (Sigma), 10% MSC-qualified-FBS (Invitrogen), 60 U/mL Pen-Strep (Invitrogen), and 2.5 μg/mL Fungizone (Sigma), based on our earlier work. The culture medium was changed every two days, and all samples were maintained at 37 °C, 5% CO₂, 95–99% relative humidity (to prevent dehydration) throughout the experiment (up to 36 days). To evaluate cell viability in the bioprinted constructs, cells were stained with fluorescent dyes of calcein-AM and propidium iodide (Live-Dead assay, Invitrogen) after bioprinting was completed.

**Quantitative RT-PCR Analysis.** Extraction and isolation of mRNA was performed separately and individually for (i) control, (ii) single phase BMP-2, (iii) single phase TGF-β, and (iv) multiphase BMP-2 and TGF-β groups using the TRIzol reagent and following the manufacturer’s RNA isolation protocol (Invitrogen). qRT-PCR array analysis was used to assess the
differentiation of hMSCs to bone, cartilage, tendon, adipose, and muscle phenotypes after 14, 21, and 36 days of culture. Genomic expression analysis was performed using the Human Mesenchymal Stem Cell RT² Profiler PCR Array (PAHS-082Z, SABiosciences, Qiagen, Valencia, CA) for the expression of 84 key genes according to manufacturer’s instructions utilizing Roche LightCycler 480 instrument. The data generated were analyzed using the SABioscience software. Normalization was performed using arithmetic mean utilizing housekeeping genes (ACTB, B2M, GAPDH, HPRT1, RPLP0). The genes were initially categorized in terms of stemness markers, MSC-specific markers, and other genes associated with MSCs. Stemness markers were grouped as FGFB, INS, LIF, POU5F1, SOX2, TERT, WNT3A, ZFP42. MSC-specific markers were categorized as ALCAM, ANPEP, BMP2, CASP3, CD44, ENG, ERBB2, FUT4, FZD9, ITGA6, ITGA3, KDR, MCAM, NGF, NTSE, PDGFRB, PROM1, THY1, VCAM1. Other genes associated with MSCs were ANXA5, BDNF, BGLAP, BMP7, COL1A1, CSF2, CSF3, CTNNB1, EGF, FUT1, GTF3A, HGF, ICAM1, IFNG, IGF1, IL10, IL1B, IL6, ITGB1, KITLG, MITF, MMP2, NES, NUDT6, PIGS, PTPRC, SLC17A5, TGF3B, TNF, VEGFA, VIM, WGF. MSC differentiation markers were categorized in four main groups: (i) genes involved in osteogenesis and chondrogenesis, namely, BMP2, BMP4, BMP6, COL1A1, ERBB2, FGFB, GDF6, HGF, IGF1, IL10, IL6, KDR, LIF, RUNX2, SOX9, TBX5, TGF1, TGF3B, VEGFA, WNT3A; (ii) genes involved in adipogenesis, namely, PPARG, RHOA, RUNX2; (iii) genes involved in myogenesis, namely, JAG1, NOTCH1; and (iv) genes involved in tenogenesis, namely, BMP2, GDF15, SMAD4, TGF1.

Pathway and Network Analysis. Comprehensive network and pathway analyses were performed using the qRT-PCR data and GeneGo Metacore Software and Database. For GeneGo Metacore pathway and network analysis, fold regulation data obtained from qRT-PCR results were used. To eliminate the noise level data points, intensity levels and fold change data were compared for each sample at each time point. Fold change values were determined relative to control group, which included only hMSCs and did not include any growth factors. According to this comparison, the genes were categorized in the following groups: (i) single phase BMP-2, (ii) single phase TGF-β, and (iii) multiphase BMP-2 and TGF-β. Before analysis, the general threshold value was set as 1.3 and the p-value was set as 0.01 for all time points and samples. Next, GO processes were determined for day 14 (Table S1 in the Supporting Information), day 21 (Table S2 in the Supporting Information), and day 36 (Table S3 in the Supporting Information) for all three categories. Similarly, pathway maps were determined for day 14 (Figure S1 and Table S4 in the Supporting Information), day 21 (Figure S2 and Table S5 in the Supporting Information), and day 36 (Figure S3 and Table S6 in the Supporting Information). Process networks were obtained for day 14 (Table S7 in the Supporting Information), day 21 (Table S8 in the Supporting Information), and day 36 (Table S9 in the Supporting Information). Finally, map folders (Figure S4 in the Supporting Information) were determined for all time points using GeneGo software.

RESULTS AND DISCUSSION

Anisotropy and Multiphase Patterning of Engineered 3D Fibrocartilage Tissue Model. We studied the distinctness and integration of the bioprinted phases by using large molecular weight fluorescent dyes, Rhodamine B (red) and Dextran-Alexa Fluor 488 (green), where red color represents the TGF-β1 phase and the green color represents the BMP-2 phase (Figure 2A—C). The printed multiphase hydrogel structure representing an anisotropic tissue unit displayed boundaries between the individual droplets immediately after printing (Figure 2D). The dyes were considered to mimic the embedded growth factors in different phases in constructs, and they were employed to visualize the anisotropy after patterning (Figure 3A). Release and delivery of growth factors from hydrogel carriers have been extensively studied for applications in tissue engineering and regenerative medicine. In this study, our aim was to retain the growth factors in the patterned hydrogel constructs together with the cells, which would assist in differentiation of embedded stem cells toward osteogenic and chondrogenic phenotypes in the patterned structures. Imaging after patterning indicated a limited integration and a gradient between the two adjacent phases, and a distinction was still present between the bulk of two phases (Figure 3A). In a smaller scale, the boundaries were observed to fade and smooth transitions emerged between the two phases after the multilayer printing process was completed.
(Figure 3A inset). The transition region in the tissue construct (indicated by the dashed line in the Figure 3A inset) was observed to be around \(\sim 1\)–\(2\) mm in length, which mimics the native fibrocartilage interface region. A similar integration pattern between the phases was considered to be present in the case of growth factor and cell patterning.

Most biomaterials and scaffolding approaches result in mismatch of compositional properties at the tissue interface due to the lack of the physiological anisotropy.\(^{52,53}\) Soft–hard tissue interfaces between tendon, ligament, cartilage, and bone are complex, and they are composed of four main zones: (i) soft tissue proper, (ii) fibrocartilage, (iii) mineralized fibrocartilage, and (iv) bone, in a microscale intricate organization.\(^{49}\) Mimicking the functional integration site of soft tendon tissue to rigid bone tissue can be attained by regenerating the fibrocartilage phase, which requires population by multiple cell types and associated ECM heterogeneity similar to a native tissue interface.\(^{7}\) An anisotropic and stratified structure is essential to mimic the mechanical, compositional and cellular features of the tissue interface. The transition occurs in a microscopic space (50 \(\mu\)m to \(\sim 1\)–\(2\) mm, depending on species and age)\(^{30,31}\) with dramatic change in cellular, ECM, and biological factor composition (Figure 1), which could be mimicked using bioprinting method.

**Morphological Organization and Characterization of Embedded Cells in Multiphase Patterned Tissue Structure.** In an earlier study, we presented an extensive genomic analysis of stem cell markers in bioprinted stem cells, which infer the proliferation potential of the printed cells.\(^{50}\) In this study, to test the viability of the cells after patterning, we performed calcein-AM and propidium iodide based viability assay on the cells. Cell viability was observed to be greater than 90\% after micropatterning (Figure 3B) in the engineered fibrocartilage phase. This result indicated that bioprinting did not significantly affect cell survival, which is consistent with our earlier studies.\(^{9,33,50,51}\) Cells displayed typical healthy morphology generally observed in hydrogels (Figure 3B).

**Genomic Expression Analysis on Single Phase and Multiphase Patterned Tissue Models.** Quantitative RT-PCR genomic expression analysis results demonstrated that most of the osteogenesis and chondrogenesis related genes analyzed were simultaneously upregulated in multiphase BMP-2 and TGF-\(\beta\) patterned constructs, especially after long-term culture (Figure 4A). Fold change values were observed to be higher for most osteogenesis and chondrogenesis related genes in the multiphase BMP-2 and TGF-\(\beta\) tissue construct compared to single phase constructs after 36 days in culture (Figure 4B). A number of tendon, muscle, and adipose tissue related genes were also expressed at lower upregulation values (Figure 5).

Various growth factors, including BMP-2 and TGF-\(\beta\) superfamily factors, have previously been immobilized in combination with ECM components by utilizing the inherent...
binding ability of these cytokines and ECM components. These factors were used in combination with bioprinting to form 2D structures to study the response and differentiation of cells, which were seeded postprinting. In this study we incorporated BMP-2 and TGF-β1 in photo-cross-linkable gelatin based hydrogel matrix in combination with hMSCs as a Bioink to

Figure 5. Genomic expression analysis results presented as a clusterogram after three different culture durations (days 14, 21, and 36) for both single phase and multiphase patterning.
form multiphase 3D tissue models. With this 3D tissue structure, we studied phenotypic differentiation and genomic expression of embedded hMSCs toward bone and cartilage, mimicking the fibrocartilage phase in skeletal system.

**Phenotypic Pathway and Network Analysis Based on Genomic Expression Data.** General pathway analysis was performed on genomic expression data to obtain a comprehensive list of all the differentiation related pathways involved in the engineered tissue model, which is an approach directly related to drug discovery and development. Activation of differentiation related mechanisms, via signaling pathways, including TGF, Wnt, BMP, and vascular endothelial growth factor (VEGF), were analyzed and presented for qRT-PCR results obtained at day 14 (Figure S1 in the Supporting Information), day 21 (Figure S2 in the Supporting Information), and day 36 (Figure S3 in the Supporting Information), with references to the relevant literature. The specific genes identified in each analysis and the statistical $p$-values calculated by the GeneGo software are presented in Tables S1–S9 in the Supporting Information. These results demonstrated that, at all the time points, differentiation related pathways were activated in the engineered fibrocartilage tissues via bone and cartilage related signaling pathways, including TGF, Wnt, BMP, and VEGF (Figures S1–S4 in the Supporting Information). In the light of the various pathways observed in this study, future studies are needed that focus on specific relevant pathways involved in differentiation of hMSCs in engineered interface tissues. The approach and the results presented in this work are directly relevant to development of new *in vitro* functional models based on stem cells and their use in drug discovery.

**SUMMARY AND CONCLUSIONS**

We present the application of emerging bioprinting technology in engineering anisotropic multiphase 3D tissue models with potential impact in *in vitro* drug testing, discovery, and development. We designed a biochemical gradient with microscale gels encapsulating hMSCs and growth factors in an organization that aims to mimic the native fibrocartilage phase. Quantitative RT-PCR analysis showed that the hMSCs displayed an upregulation of osteogenesis and chondrogenesis related genes simultaneously in the 3D fibrocartilage model. Phenotypic pathway and network analysis results were presented based on the genomic expression data obtained from the model. Bioprinted microscale anisotropic tissue structures can potentially be utilized as functional *in vitro* 3D tissue models and platforms for high-throughput pharmaceutical testing and validation studies. Functional tissue models coupled with comprehensive genomic expression analysis on high-content biomarkers via bioinformatics data mining tools open new venues in drug testing and discovery. These methods and platforms would ultimately allow the use of a patient’s own cells for generating personalized *in vitro* functional tissue models as testbeds for assessing drug candidates and therapeutics.

**ASSOCIATED CONTENT**

Supporting Information
Pathway maps, map folder results, tables of GO processes, tables of pathway maps, and tables of process networks. This material is available free of charge via the Internet at http://pubs.acs.org.

**AUTHOR INFORMATION**

*E-mail: umut@case.edu, udemirci@rics.bwh.harvard.edu.*

**Notes**

The authors declare the following competing financial interest(s): Utkan Demirci (U.D.) is a founder of, and has an equity interest in, DXNow, a company that is developing microfluidic and imaging technologies for point-of-care diagnostic solutions. U.D.’s interests were reviewed and are managed by the Brigham and Women’s Hospital and Partners HealthCare in accordance with their conflict of interest policies.

**ACKNOWLEDGMENTS**

This work was conducted with support from Harvard Catalyst, The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health Award 8UL1TR000170-05 and financial contributions from Harvard University and its affiliated academic health care centers). The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic health care centers, or the National Institutes of Health. Utkan Demirci (U.D.) acknowledges that this material is based in part upon work supported by the National Science Foundation under NSF CAREER Award Number 1150733 and NIH R21HL112114. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the National Science Foundation.

**REFERENCES**

Molecular Pharmaceutics


(34) Fabien, G.; Mironov, V.; Nakamura, K. Bioprinting is coming of age: report from the International Conference on Bioprinting and Biofabrication in Bordeaux (3B’09). *Biofabrication* 2010, 2 (1), 012021.


